Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Experimental Dermatology|December 17, 2010
Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseasesArne von Bonin, Alexandra Rausch, Anne Mengel, et al.
Oncotarget|November 22, 2017
Isolation of circulating tumor cells from pancreatic cancer by automated filtrationNora Brychta, Michael Drosch, Christiane Driemel, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Journal of Neurochemistry|March 11, 2004
Identification of regulated genes during permanent focal cerebral ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4Armin Schneider, Rico Laage, Oliver von Ahsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate CancerStefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, et al.
Molecular Oncology|January 15, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In VivoGerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Molecular Cancer Therapeutics|February 3, 2016
Novel Mps1 Kinase Inhibitors with Potent Antitumor ActivityAntje M Wengner, Gerhard Siemeister, Marcus Koppitz, et al.
Molecular Cancer Therapeutics|March 16, 2017
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung CancerJörg Willuda, Lars Linden, Hans-Georg Lerchen, et al.
Oncoimmunology|February 10, 2022
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interactionJessica Pinkert, Hans-Henning Boehm, Mark Trautwein, et al.
Pageof 3